Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PKLR | P30613 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8216038 | 0.88 | KCNN4 (0.41) | CA12CA1CA2CA3CA4 | |
| SCHEMBL2759895 | 0.83 | CA12 (0.65) | CA12CA1CA2CA3CA4 | |
| SCHEMBL225206 | 0.83 | CA12 (0.65) | CA12CA1CA2CA3CA4 | |
| SCHEMBL7656123 | 0.83 | MTNR1A (0.45) | NPSR1LMNAPPARGPPARA | |
| SCHEMBL7656116 | 0.83 | MTNR1A (0.45) | NPSR1LMNAPPARGPPARA | |
| SCHEMBL18555414 | 0.82 | ALDH1A1 (0.38) | KCNN4NPSR1PKLRMAPTALDH1A1 | |
| SCHEMBL2748097 | 0.82 | ALDH1A1 (0.38) | KCNN4NPSR1PKLRMAPTALDH1A1 | |
| SCHEMBL21837578 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL21837576 | 0.82 | KDM4E (0.43) | KDM4EALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL2742288 | 0.81 | KCNN4 (0.46) | KCNN4NPSR1ALDH1A1LMNAKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2067765-A2 | Intermediate compounds and their use in preparation of lacosamide | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | claimed |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-06-04 | — | — | US | claimed |
| EP-2444390-B1 | Process for producing Lacosamide | EUTICALS GMBH (DE) | 2017-02-01 | — | — | EP | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| US-8957252-B2 | Process for preparation of lacosamide and some N-benzyl-propanamide intermediate derivatives | INDOCO REMEDIES LIMITED (IN) | 2015-02-17 | — | — | US | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| EP-2598476-B1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LTD (IN) | 2014-07-02 | — | — | EP | disclosed |
| US-8759582-B2 | Process for the preparation of lacosamide | NATCO PHARMA LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| EP-2598476-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | Indoco Remedies Limited (IN) | 2013-06-05 | — | — | EP | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2013-05-16 | — | — | US | disclosed |
| WO-2012014226-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | INDOCO REMEDIES LIMITED (IN) | 2012-02-02 | — | — | WO | disclosed |
| US-8093426-B2 | 2-tritylamino-3-(hydroxy or methoxy)propionic acid, or corresponding benzylamide thereof as chemical intermediate; chirally pure lacosamide; high purity | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-10 | — | — | US | disclosed |
| US-8093426-B2 | 2-tritylamino-3-(hydroxy or methoxy)propionic acid, or corresponding benzylamide thereof as chemical intermediate; chirally pure lacosamide; high purity | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-10 | — | — | US | disclosed |
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | RANBAXY LABORATORIES LIMITED (IN) | 2012-01-05 | — | — | US | disclosed |
| EP-2399901-A1 | Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide | Archimica GmbH (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2067765-A2 | Intermediate compounds and their use in preparation of lacosamide | Ranbaxy Laboratories Limited (IN) | 2009-06-10 | — | — | EP | disclosed |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-06-04 | — | — | US | disclosed |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004452-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
| US-20130123522-A1 | PROCESS FOR PREPARATION OF LACOSAMIDE AND SOME N-BENZYL-PROPANAMIDE INTERMEDIATE DERIVATIVES | LPXN, CACNA1B, PMP22 | CA12 138/4885CA1 78/4885CA2 119/4885 |
| US-20120004462-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
| US-20090143472-A1 | INTERMEDIATE COMPOUNDS AND THEIR USE IN PREPARATION OF LACOSAMIDE | HDAC2, HDAC5, SCN5A | CA12 11/4885CA1 10/4885CA2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.